Twin Tree Management LP acquired a new position in shares of GlaxoSmithKline (NYSE:GSK) during the first quarter, HoldingsChannel.com reports. The institutional investor acquired 19,304 shares of the pharmaceutical company’s stock, valued at approximately $754,000.
A number of other hedge funds also recently added to or reduced their stakes in GSK. Field & Main Bank acquired a new stake in GlaxoSmithKline during the fourth quarter worth approximately $132,000. Amussen Hunsaker Associates LLC acquired a new position in shares of GlaxoSmithKline in the 4th quarter valued at $141,000. First Dallas Securities Inc. acquired a new position in shares of GlaxoSmithKline in the 4th quarter valued at $142,000. Centaurus Financial Inc. acquired a new position in shares of GlaxoSmithKline in the 1st quarter valued at $157,000. Finally, Whittier Trust Co. increased its holdings in shares of GlaxoSmithKline by 71.0% in the 1st quarter. Whittier Trust Co. now owns 4,520 shares of the pharmaceutical company’s stock valued at $177,000 after acquiring an additional 1,876 shares during the period. 11.12% of the stock is currently owned by institutional investors.
GlaxoSmithKline opened at $40.03 on Friday, Marketbeat.com reports. GlaxoSmithKline has a 1-year low of $34.52 and a 1-year high of $44.53. The company has a debt-to-equity ratio of 3.90, a quick ratio of 0.40 and a current ratio of 0.61. The firm has a market capitalization of $99.43 billion, a P/E ratio of 13.90, a PEG ratio of 2.06 and a beta of 0.82.
GlaxoSmithKline (NYSE:GSK) last posted its quarterly earnings data on Wednesday, April 25th. The pharmaceutical company reported $0.68 earnings per share for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.02). GlaxoSmithKline had a net margin of 3.50% and a return on equity of 144.84%. The firm had revenue of $10.04 billion during the quarter, compared to analysts’ expectations of $10.26 billion. analysts forecast that GlaxoSmithKline will post 2.95 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 12th. Investors of record on Friday, May 11th will be given a $0.5298 dividend. The ex-dividend date is Thursday, May 10th. This represents a $2.12 dividend on an annualized basis and a yield of 5.29%. GlaxoSmithKline’s dividend payout ratio (DPR) is 72.92%.
GSK has been the topic of a number of recent research reports. Kepler Capital Markets raised shares of GlaxoSmithKline from a “reduce” rating to a “hold” rating in a report on Friday, February 9th. Zacks Investment Research raised shares of GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a report on Wednesday, April 18th. ValuEngine cut shares of GlaxoSmithKline from a “hold” rating to a “sell” rating in a report on Friday, May 4th. Cowen reaffirmed a “hold” rating and issued a $40.00 target price on shares of GlaxoSmithKline in a report on Thursday, February 15th. Finally, Deutsche Bank reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a report on Wednesday, March 28th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the company. GlaxoSmithKline presently has an average rating of “Hold” and a consensus price target of $40.21.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.